疏血通注射液联合低分子肝素、华法令治疗肺栓塞的临床观察  

Clinical Observation on Pulmonary Embolism Treated with Shuxuetong Injection Combined Low Molecular Heparin and Warfarin

作　　者：孙为勤[1] 薛蓉[1] 

机构地区：[1]大同市第三人民医院心血管内科,山西大同037008

出　　处：《山西大同大学学报（自然科学版）》2015年第1期36-38,共3页Journal of Shanxi Datong University(Natural Science Edition)

摘　　要：目的探讨疏血通注射液联合低分子肝素及华法令抗凝治疗肺栓塞的临床疗效及安全性。方法选取急性肺栓塞住院患者81例,分为2组:疏血通联合低分子肝素、华法令治疗组为试验组,共48例;低分子肝素及华法令治疗组为对照组,共33例。通过比较2组治疗后临床症状,血气分析结果,肺动脉CT或核素通气/灌注恢复情况,了解治疗效果。通过比较凝血指标,了解治疗的安全性。结果治疗7 d,试验组临床症状改善率为83.33%,对照组为66.64%,2组比较差异有统计学意义。治疗14 d临床症状改善情况及通气指标,凝血指标比较,2组均无显著差异。结论疏血通联合抗凝治疗在治疗7d的临床症状改善方面优于单纯抗凝治疗组,且治疗安全性好。Objective To investigate the clinical efficiency and safety of Shuxuetong Injection combined with low molecular heparin and warfarin for treating pulmonary embolism. Methods Eighty-one patients with acute pulmonary embolism, were randomly divided into treatment and control groups. The patients in the treatment group were treated with Shuxuetong Injection combined low molecular heparin and warfarin, and those in the control group were treated with low molecular heparin and warfarin. Clinical symptoms（ such as dyspnea and chest pain）, results of the blood-gas analysis, images of CT of pulmonary artery or ventilation and perfusion scintigraphy in the patients were compared after treatment between the different groups to measure treatment effect, coagulation indices used to evaluate safety. Results Seven days after treatment, ameliorative rate of symptom in treatment group was 83.33%, and in control groups was 66.64%. There were significant differences between each other. Fourteen days after treatment, ameliorative rate of symptom, ventilate indices and coagulation indices between the 2 groups were not obviously different. Conclusion The method of Shuxuetong Injection combined with low molecular heparin and warfarin is better than pure anticoagulation at improving symptoms after seven days＇ treatment and possesses good safety.

关 键 词：肺栓塞 疏血通注射液 抗凝治疗 华法令 低分子肝素 

分 类 号：R563.5[医药卫生—呼吸系统]